Status:
ACTIVE_NOT_RECRUITING
Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborating Sponsors:
Children's Hospital of Chongqing Medical University
children and women' hospital of Jiangxi
Conditions:
Necrotizing Enterocolitis
Preterm
Eligibility:
All Genders
24-31 years
Phase:
NA
Brief Summary
Necrotizing enterocolitis (NEC) is one of the most common and severe gastrointestinal emergencies during the neonatal period, especially among preterm infants. In high-income countries such as Finland...
Detailed Description
Although the pathophysiology of NEC is not fully understood, epidemiological studies strongly suggest a multifactorial cause, involving infection and inflammation, premature birth, hypoxic-ischemia, i...
Eligibility Criteria
Inclusion
- gestational age at delivery between 24+0 and 31+6 weeks
- initiation of enteral nutrition within 24 hours after birth.
Exclusion
- parental decision to not participate
- presence of major congenital anomalies
- requirement for surgical intervention prior to randomization.
- The subject would be considered censored if the study ended due to one of the following conditions:
- 1\. Death
- 2\. Parents' decision to withdraw participation
- 3\. Discharge based on doctors' recommendations.
- Once enrolled, the neonates received minimal enteral nutrition within the first 24 hours after birth for the initial three days. Following this period, both groups of neonates were fed expressed milk using a pumping system.
- the milk temperature was measured using the following steps:
- 1\) During the first week after birth, each preterm infant had two identical pumping setups. One pump was used for feeding according to group allocation, while the second, set to zero velocity, was used to measure milk temperature
- 2\) The temperature from the second pump, taken at the same time milk entered the stomach from the first pump, was recorded as the final milk temperature
- 3\) After the first week, only one pump was used per infant, and the temperature of the last 1 ml of milk was measured as the final temperature.
- Both groups were supplemented with human milk fortifier (HMF) for preterm infants weighing 1800 g or less. The neonates were fed 50 ml/kg/day of breast milk, following the Chinese Expert Consensus on the Use of Breast Milk Fortifiers in Premature Infants. The milk was sourced from the infant's mother. Initially, infants received half-strength fortified milk for 3-7 days before transitioning to full-strength fortified milk. HMF was discontinued once the infant's body weight reached the 25th-50th percentile for appropriate-for-gestational-age infants or the 10th percentile for small-for-gestational-age infants, depending on sex and gestational age. The choice of formula, HMF, and the decision to add lactase was at the discretion of the attending neonatologist.
- Weaning from thermostatic feeding would occur if any of the following conditions were met:
- 1\) If no signs of feeding intolerance (FI) appeared after administering pumped milk within 15 minutes for 1-2 days, thermostatic feeding would transition to standard feeding
- 2\) The feeding duration could be gradually reduced in 10-minute increments down to a minimum of 15 minutes. Weaning from standard feeding would occur if no FI was observed after oral feeding within 30 minutes for 1-2 days.
- Due to the lack of existing intervention-based evidence for reference, we based our sample size calculation on an RCT that examined the impact of feeding patterns (human milk-based diet vs. bovine milk-based products). According to the published data, the incidence of NEC was significantly lower in infants receiving an exclusively human-milk-based diet (4.5%) compared to those receiving bovine milk-based products (15.9%; p = 0.04), with approximately 10% in difference of incidence. Using previously published data on NEC prevention, we conducted a power analysis for a superiority clinical trial. To achieve 80% power with a 5% Type I error rate (α = 0.05), we estimated a sample size of 100 participants per group (n₁ = 100, n₂ = 100). Considering a 20% loss to follow-up, we adjusted the sample size to 120 participants per group to ensure adequate power to detect an approximately 10% difference in NEC incidence between the intervention and control groups (R version 4.2.2).
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06908239
Start Date
September 1 2024
End Date
December 31 2029
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chongqing Health Center for Women and Children
Chongqing, Chongqing Municipality, China, 401147